Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 11479 | 10.45 |
09:34 ET | 2803 | 10.41 |
09:36 ET | 1376 | 10.36 |
09:38 ET | 11088 | 10.43 |
09:39 ET | 1416 | 10.43 |
09:41 ET | 2001 | 10.4 |
09:43 ET | 2435 | 10.42 |
09:45 ET | 600 | 10.385 |
09:48 ET | 4871 | 10.35 |
09:50 ET | 910 | 10.35 |
09:52 ET | 43036 | 10.32 |
09:54 ET | 2722 | 10.325 |
09:56 ET | 1324 | 10.32 |
09:57 ET | 86177 | 10.25 |
09:59 ET | 2481 | 10.23 |
10:01 ET | 1497 | 10.215 |
10:03 ET | 5849 | 10.33 |
10:06 ET | 2300 | 10.36 |
10:08 ET | 1700 | 10.38 |
10:10 ET | 1735 | 10.41 |
10:12 ET | 4769 | 10.48 |
10:14 ET | 2463 | 10.51 |
10:15 ET | 300 | 10.505 |
10:17 ET | 2377 | 10.4752 |
10:19 ET | 2413 | 10.48 |
10:21 ET | 4100 | 10.5 |
10:24 ET | 3430 | 10.5189 |
10:26 ET | 9218 | 10.48 |
10:28 ET | 2710 | 10.51 |
10:30 ET | 1000 | 10.495 |
10:32 ET | 1695 | 10.475 |
10:33 ET | 3003 | 10.435 |
10:35 ET | 1205 | 10.44 |
10:37 ET | 300 | 10.435 |
10:39 ET | 2313 | 10.405 |
10:42 ET | 1718 | 10.39 |
10:44 ET | 655 | 10.37 |
10:46 ET | 4012 | 10.38 |
10:48 ET | 570 | 10.38 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.4B | -2.3x | --- |
Arcus Biosciences Inc | 1.4B | -3.8x | --- |
Prothena Corporation PLC | 1.2B | -8.4x | --- |
Protagonist Therapeutics Inc | 1.5B | -17.6x | --- |
Immatics NV | 1.1B | -8.3x | --- |
4D Molecular Therapeutics Inc | 1.3B | -10.4x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $86.2M |
Shares Outstanding | 135.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.47 |
EPS | $-4.59 |
Book Value | $11.80 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 16.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -794.04% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.